Other active comparator
Cagrilintide
OTHER_ACTIVE_cagrilintide
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -2.35 (-12.41 to 8.07) | 0.40 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -2.25 (-14.06 to 9.77) | 0.47 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.40 (-11.50 to 1.60) | 0.45 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.38 (-11.45 to 1.61) | 0.48 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.26 (-11.31 to 2.03) | 0.36 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.25 (-11.79 to 2.39) | 0.46 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.42 (0.54 to 4.08) | 0.43 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.47 (0.57 to 4.08) | 0.46 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.62 (0.52 to 6.10) | 0.54 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.65 (0.50 to 6.59) | 0.60 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.66 (1.79 to 4.07) | 0.67 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.57 (1.71 to 3.95) | 0.65 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.36 (0.69 to 2.76) | 0.83 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.45 (0.65 to 3.25) | 0.81 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.10 (0.58 to 2.14) | 0.74 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.13 (0.57 to 2.27) | 0.73 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.41 (0.70 to 3.05) | 0.65 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.40 (0.73 to 2.85) | 0.64 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 3.31 (0.37 to 58.12) | 0.30 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 3.45 (0.37 to 62.57) | 0.30 |